BIOBank

Leading French human tissue bank specialising in bone allografts

Founded in 1999 and headquartered in Lieusaint, France, BIOBank (“the Company”) is a leading manufacturer and distributor of bone allografts for orthopaedic, spine, dental and cranio-maxillofacial surgeries. Considered the gold standard for replacing damaged or diseased bone tissues, allografts are taken from another individual’s tissues and obtained from femoral heads collected during surgery performed on living donors.

With approximately 50 employees, BIOBank serves 1,700 customers in France and addresses eight additional international markets, both directly through its own distributor in Switzerland and indirectly through a network of third-party distributors in other geographies. The Company has a presence across the entire value chain, including collecting bone tissue from more than 160 partner healthcare institutions, through to processing and distribution.

IK Partners acquired a majority stake in BIOBank in August 2024, from Verto Growth, Capital Croissance and the management team; all of whom remain significantly invested.

What Attracted Us to the Business

• Resilient and growing bone graft market with high barriers to entry
• Strong leadership position
• High-performance proprietary industrial process (Supercrit®) and unique expertise
• One of only three private processing tissue banks in France approved by the national drug safety agency (ANSM)

Our Value Creation Strategy

We are working alongside management to:

• Continue to innovate and expand the product offering;
• Cement the Company’s leadership position by driving consolidation in the market;
• Pursue internationalisation through the expansion and reinforcement of distribution networks; and
• Execute a selective buy-and-build strategy.

Quote from the Client

“We are very much looking forward to teaming up with IK’s highly experienced team, alongside our existing investor base. Their focus on international platform expansion and proven track record in the European Healthcare sector will be crucial to our continued growth as we pursue new markets and product development. We would like to thank Verto and Capital Croissance for their invaluable support thus far and look forward to embarking on this new chapter.”

Alexandre Tepas, Chief Executive Officer, BIOBank